Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.
Saved in:
| Title: | Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts. |
|---|---|
| Authors: | Òdena A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Universitat de Barcelona (UB), Barcelona, Spain., Monserrat L; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Institute of Cancer and Blood Disease, Hospital Clinic of Barcelona, Barcelona, Spain.; Reveal Genomics, Barcelona, Spain., García-Galea E; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Casals E; Universitat de Barcelona (UB), Barcelona, Spain.; Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain., Molina C; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., Herencia-Ropero A; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Pedretti F; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Domènech H; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain., Guzmán M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Rodríguez O; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Grueso J; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Esteve-Codina A; Universitat de Barcelona (UB), Barcelona, Spain.; Centro Nacional de Análisis Genómico (CNAG), Barcelona, Spain., Dienstmann R; Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.; University of Vic - Central University of Catalonia, Vic, Spain., Chandarlapaty S; Departments of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Center for Molecular-Based Therapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fan PD; Research and Development, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Suto F; Research and Development, Daiichi Sankyo, Inc, Basking Ridge, NJ, USA., Oliveira M; Medical Oncology Department, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.; Breast Cancer Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Institute of Cancer and Blood Disease, Hospital Clinic of Barcelona, Barcelona, Spain.; Reveal Genomics, Barcelona, Spain.; Department of Medicine, University of Barcelona, Barcelona, Spain.; Institute of Oncology (IOB) - Hospital Quirón Salud, Barcelona, Spain., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. vserra@vhio.net. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2025 Nov 21; Vol. 9 (1), pp. 393. Date of Electronic Publication: 2025 Nov 21. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
